- Home
- CMRX vs NTRB Comparison
CMRX vs NTRB Comparison
Compare CMRX & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMRX
- NTRB
- Stock Information
- Founded
- CMRX 2000
- NTRB 2016
- Country
- CMRX United States
- NTRB United States
- Employees
- CMRX N/A
- NTRB N/A
- Industry
- CMRX Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- CMRX Health Care
- NTRB Health Care
- Exchange
- CMRX Nasdaq
- NTRB Nasdaq
- Market Cap
- CMRX 77.1M
- NTRB 77.9M
- IPO Year
- CMRX 2013
- NTRB N/A
- Fundamental
- Price
- CMRX $0.86
- NTRB $4.73
- Analyst Decision
- CMRX Strong Buy
- NTRB
- Analyst Count
- CMRX 1
- NTRB 0
- Target Price
- CMRX $11.00
- NTRB N/A
- AVG Volume (30 Days)
- CMRX 282.9K
- NTRB 18.3K
- Earning Date
- CMRX 11-07-2024
- NTRB 12-11-2024
- Dividend Yield
- CMRX N/A
- NTRB N/A
- EPS Growth
- CMRX N/A
- NTRB N/A
- EPS
- CMRX N/A
- NTRB N/A
- Revenue
- CMRX $159,000.00
- NTRB $1,803,816.00
- Revenue This Year
- CMRX $1,772.84
- NTRB N/A
- Revenue Next Year
- CMRX N/A
- NTRB N/A
- P/E Ratio
- CMRX N/A
- NTRB N/A
- Revenue Growth
- CMRX N/A
- NTRB N/A
- 52 Week Low
- CMRX $0.75
- NTRB $2.09
- 52 Week High
- CMRX $1.30
- NTRB $9.60
- Technical
- Relative Strength Index (RSI)
- CMRX 41.07
- NTRB 35.59
- Support Level
- CMRX $0.91
- NTRB $4.63
- Resistance Level
- CMRX $1.12
- NTRB $5.33
- Average True Range (ATR)
- CMRX 0.09
- NTRB 0.39
- MACD
- CMRX -0.01
- NTRB -0.13
- Stochastic Oscillator
- CMRX 10.31
- NTRB 5.65
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.